NCT07338331Completed
Comparative Effects of Aspirin, Metformin and SGLT2 Inhibitors on Liver Enzymes, Lipid Profile, and FibroScan Findings in Non-Alcoholic Fatty Liver Disease
Comparison Between the Effect of Aspirin, Metformin, and SGLT2 Inhibitor Intake in Non-Alcoholic Fatty Liver on Liver Enzymes, Lipid Profile, and the Results of FibroScan
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
Non-alcoholic fatty liver disease (NAFLD), currently referred to as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common hepatic manifestation of metabolic dysfunction and may progress from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. This randomized clinical trial evaluated and compared three pharmacological approaches with different mechanisms of action: low-dose aspirin as an anti-inflammatory and antiplatelet therapy, dapagliflozin as a sodium-glucose cotransporter-2 (SGLT2) inhibitor with metabolic effects, and metformin as an insulin-sensitizing therapy. The study assessed their effects on liver enzymes, lipid profile, and FibroScan-derived measures of hepatic steatosis and liver stiffness over a 6-month treatment period.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 20 Dec 2025
- Start date
- 4 Apr 2023
- Primary completion date
- 5 Apr 2025
- Lead sponsor
- Galala University
- NCT number
- NCT07338331
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 4 Apr 2023 to the primary completion date, 5 Apr 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active chronic viral hepatitis or autoimmune liver disease.
- History of gastrointestinal bleeding or other contraindications for Aspirin.
- Severe renal insufficiency.
Other
- Pregnancy or breastfeeding.
- Alcohol intake
Who the study is looking for
- Diabetes mellitus, unless receiving only Dapagliflozin for treatment.
- Adult individuals (18-65 years) with a clinical diagnosis of NAFLD based on liver ultrasound
- No history of alcohol consumption or consumption within 3 months.
- Absence of other liver diseases.
- No significant renal or gastrointestinal issues that could interfere with treatment.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Faculty of Pharmacy Coordinator of this site? Confirm its status | Banī Suwayf | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.